Cancer Chemotherapy Center

Secreted PD-L1 variants mediate resistance to PD-L1 blockade therapy in non-small cell lung cancer More

To identify molecular targets and compounds for cancer therapy

We discover and develop the novel molecular-targeted drugs by using Cancer Cell Informatics.

Telomeres, cell immortality and cancer stemness as therapeutic targets

We promote genome science-driven research for targeted therapy and personalized medicine

We focus the research between clinical samples and imaging the molecular target

Kawakami, R., Mashima, T., Kawata, N., Kumagai, K., Migita, T., Sano, T., Mizunuma, N., Yamaguchi, K. and Seimiya, H.

ALDH1A3‐mTOR axis as a therapeutic target for anticancer drug‐tolerant persister cells in gastric cancer.
Cancer Sci., in press (2020)
Takahashi, K., Seto, Y., Okada, K., Uematsu, S., Uchibori, K., Tsukahara, M., Oh-hara, T., Fujita, N., Yanagitani, N., Nishio, M., Okubo, K. and Katayama, R.

Overcoming resistance by ALK compound mutation (I1171S + G1269A) after sequential treatment of multiple ALK inhibitors in non-small cell lung cancer.
Thorac. Cancer, in press (2020)
Jang, M. K., Mashima, T. and Seimiya, H.

Tankyrase inhibitors target colorectal cancer stem cells via AXIN-dependent downregulation of c-KIT tyrosine kinase.
Mol. Cancer Ther., in press (2020)
Tanaka, N., Takahara, A., Hagio, T., Nishiko, R., Kanayama, J., Gotoh, O. and Mori, S.

Sequencing artifacts derived from a library preparation method using enzymatic fragmentation.
PLoS One, 15, e0227427 (2020)
Mizutani, A. and Seimiya, H.

Tankyrase promotes primary precursor miRNA processing to precursor miRNA.
Biochem. Biophys. Res. Commun., in press (2019)